CN106852725A - Composition for improving skin - Google Patents
Composition for improving skin Download PDFInfo
- Publication number
- CN106852725A CN106852725A CN201611106057.5A CN201611106057A CN106852725A CN 106852725 A CN106852725 A CN 106852725A CN 201611106057 A CN201611106057 A CN 201611106057A CN 106852725 A CN106852725 A CN 106852725A
- Authority
- CN
- China
- Prior art keywords
- skin
- fisetin
- mentioned
- composition
- wrinkle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 107
- XHEFDIBZLJXQHF-UHFFFAOYSA-N fisetin Chemical compound C=1C(O)=CC=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 XHEFDIBZLJXQHF-UHFFFAOYSA-N 0.000 claims abstract description 170
- 235000011990 fisetin Nutrition 0.000 claims abstract description 85
- 230000037303 wrinkles Effects 0.000 claims abstract description 58
- 239000002537 cosmetic Substances 0.000 claims abstract description 50
- 239000004480 active ingredient Substances 0.000 claims abstract description 27
- 230000007423 decrease Effects 0.000 claims abstract description 26
- 108010035532 Collagen Proteins 0.000 claims abstract description 24
- 102000008186 Collagen Human genes 0.000 claims abstract description 24
- 229920001436 collagen Polymers 0.000 claims abstract description 24
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 18
- 230000009759 skin aging Effects 0.000 claims abstract description 17
- 238000003786 synthesis reaction Methods 0.000 claims abstract description 17
- 230000032683 aging Effects 0.000 claims abstract description 13
- 230000002265 prevention Effects 0.000 claims abstract description 13
- 230000001737 promoting effect Effects 0.000 claims abstract description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 32
- -1 pulvis Substances 0.000 claims description 21
- 238000009472 formulation Methods 0.000 claims description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 19
- 239000008194 pharmaceutical composition Substances 0.000 claims description 19
- 239000002674 ointment Substances 0.000 claims description 18
- 230000037394 skin elasticity Effects 0.000 claims description 18
- 230000036541 health Effects 0.000 claims description 15
- 235000013376 functional food Nutrition 0.000 claims description 13
- 230000008859 change Effects 0.000 claims description 12
- 239000000839 emulsion Substances 0.000 claims description 11
- 239000000243 solution Substances 0.000 claims description 11
- 239000006071 cream Substances 0.000 claims description 10
- 239000006210 lotion Substances 0.000 claims description 10
- 208000028990 Skin injury Diseases 0.000 claims description 9
- 201000010099 disease Diseases 0.000 claims description 9
- 239000004094 surface-active agent Substances 0.000 claims description 9
- 239000000516 sunscreening agent Substances 0.000 claims description 7
- 206010015150 Erythema Diseases 0.000 claims description 6
- 239000012459 cleaning agent Substances 0.000 claims description 6
- 239000000499 gel Substances 0.000 claims description 6
- 231100000321 erythema Toxicity 0.000 claims description 5
- 239000008187 granular material Substances 0.000 claims description 5
- 239000006072 paste Substances 0.000 claims description 5
- 239000006187 pill Substances 0.000 claims description 5
- 239000000344 soap Substances 0.000 claims description 5
- 239000000725 suspension Substances 0.000 claims description 5
- 239000006188 syrup Substances 0.000 claims description 5
- 235000020357 syrup Nutrition 0.000 claims description 5
- 239000007864 aqueous solution Substances 0.000 claims description 4
- 230000001815 facial effect Effects 0.000 claims description 4
- 229940100688 oral solution Drugs 0.000 claims description 4
- 239000007921 spray Substances 0.000 claims description 4
- 239000000375 suspending agent Substances 0.000 claims description 4
- 239000003125 aqueous solvent Substances 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 230000000475 sunscreen effect Effects 0.000 claims description 3
- 230000002792 vascular Effects 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 32
- 229920002683 Glycosaminoglycan Polymers 0.000 abstract description 30
- 235000013305 food Nutrition 0.000 abstract description 26
- 239000000463 material Substances 0.000 abstract description 15
- 239000003814 drug Substances 0.000 abstract description 14
- 230000001976 improved effect Effects 0.000 abstract description 3
- 210000003491 skin Anatomy 0.000 description 101
- 238000004519 manufacturing process Methods 0.000 description 21
- 238000000034 method Methods 0.000 description 21
- 235000013361 beverage Nutrition 0.000 description 19
- 230000006872 improvement Effects 0.000 description 19
- 230000000052 comparative effect Effects 0.000 description 14
- 239000000796 flavoring agent Substances 0.000 description 14
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 13
- 230000014509 gene expression Effects 0.000 description 12
- 230000006870 function Effects 0.000 description 11
- 239000000546 pharmaceutical excipient Substances 0.000 description 11
- 230000009467 reduction Effects 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 235000013355 food flavoring agent Nutrition 0.000 description 10
- 239000003755 preservative agent Substances 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 235000014113 dietary fatty acids Nutrition 0.000 description 7
- 239000003085 diluting agent Substances 0.000 description 7
- 239000000194 fatty acid Substances 0.000 description 7
- 229930195729 fatty acid Natural products 0.000 description 7
- 235000011187 glycerol Nutrition 0.000 description 7
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 6
- 239000000654 additive Substances 0.000 description 6
- 150000001720 carbohydrates Chemical class 0.000 description 6
- 235000014633 carbohydrates Nutrition 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 235000015097 nutrients Nutrition 0.000 description 6
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 102000016942 Elastin Human genes 0.000 description 5
- 108010014258 Elastin Proteins 0.000 description 5
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 5
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 5
- 229930006000 Sucrose Natural products 0.000 description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
- 230000000996 additive effect Effects 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 238000004040 coloring Methods 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 229920002549 elastin Polymers 0.000 description 5
- 229920001971 elastomer Polymers 0.000 description 5
- 210000002744 extracellular matrix Anatomy 0.000 description 5
- 210000002950 fibroblast Anatomy 0.000 description 5
- 235000013373 food additive Nutrition 0.000 description 5
- 239000002778 food additive Substances 0.000 description 5
- 210000002510 keratinocyte Anatomy 0.000 description 5
- 235000016709 nutrition Nutrition 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 230000002335 preservative effect Effects 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 238000003753 real-time PCR Methods 0.000 description 5
- 239000003381 stabilizer Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000005720 sucrose Substances 0.000 description 5
- 239000002562 thickening agent Substances 0.000 description 5
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 4
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 239000001512 FEMA 4601 Substances 0.000 description 4
- 102000003918 Hyaluronan Synthases Human genes 0.000 description 4
- 108090000320 Hyaluronan Synthases Proteins 0.000 description 4
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 235000010443 alginic acid Nutrition 0.000 description 4
- 229920000615 alginic acid Polymers 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 239000000806 elastomer Substances 0.000 description 4
- 239000003995 emulsifying agent Substances 0.000 description 4
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 229920002674 hyaluronan Polymers 0.000 description 4
- 229960003160 hyaluronic acid Drugs 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 235000012149 noodles Nutrition 0.000 description 4
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 235000019203 rebaudioside A Nutrition 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 238000010839 reverse transcription Methods 0.000 description 4
- 235000015067 sauces Nutrition 0.000 description 4
- 235000013599 spices Nutrition 0.000 description 4
- 150000005846 sugar alcohols Polymers 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 150000003722 vitamin derivatives Chemical class 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- KKAJSJJFBSOMGS-UHFFFAOYSA-N 3,6-diamino-10-methylacridinium chloride Chemical compound [Cl-].C1=C(N)C=C2[N+](C)=C(C=C(N)C=C3)C3=CC2=C1 KKAJSJJFBSOMGS-UHFFFAOYSA-N 0.000 description 3
- 239000004375 Dextrin Substances 0.000 description 3
- 229920001353 Dextrin Polymers 0.000 description 3
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 229920002230 Pectic acid Polymers 0.000 description 3
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 3
- 239000000783 alginic acid Substances 0.000 description 3
- 229960001126 alginic acid Drugs 0.000 description 3
- 150000004781 alginic acids Chemical class 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 229910000019 calcium carbonate Inorganic materials 0.000 description 3
- 229960000541 cetyl alcohol Drugs 0.000 description 3
- 235000013351 cheese Nutrition 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000000084 colloidal system Substances 0.000 description 3
- 210000002808 connective tissue Anatomy 0.000 description 3
- 235000019425 dextrin Nutrition 0.000 description 3
- 150000002016 disaccharides Chemical class 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 239000003792 electrolyte Substances 0.000 description 3
- 210000002615 epidermis Anatomy 0.000 description 3
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 150000002191 fatty alcohols Chemical class 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 239000010408 film Substances 0.000 description 3
- 235000020510 functional beverage Nutrition 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 230000003020 moisturizing effect Effects 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 239000003002 pH adjusting agent Substances 0.000 description 3
- 239000003973 paint Substances 0.000 description 3
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 3
- 239000010318 polygalacturonic acid Substances 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000000811 xylitol Substances 0.000 description 3
- 235000010447 xylitol Nutrition 0.000 description 3
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 3
- 229960002675 xylitol Drugs 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 description 2
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 2
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 2
- 108090000672 Annexin A5 Proteins 0.000 description 2
- 244000105624 Arachis hypogaea Species 0.000 description 2
- 108010011485 Aspartame Proteins 0.000 description 2
- 229920001287 Chondroitin sulfate Polymers 0.000 description 2
- 244000060011 Cocos nucifera Species 0.000 description 2
- 235000013162 Cocos nucifera Nutrition 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- 229920000045 Dermatan sulfate Polymers 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 238000011891 EIA kit Methods 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- 229920002971 Heparan sulfate Polymers 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 229920000288 Keratan sulfate Polymers 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229930182558 Sterol Natural products 0.000 description 2
- 244000228451 Stevia rebaudiana Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 102000006463 Talin Human genes 0.000 description 2
- 108010083809 Talin Proteins 0.000 description 2
- LPQOADBMXVRBNX-UHFFFAOYSA-N ac1ldcw0 Chemical compound Cl.C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN3CCSC1=C32 LPQOADBMXVRBNX-UHFFFAOYSA-N 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000000605 aspartame Substances 0.000 description 2
- 235000010357 aspartame Nutrition 0.000 description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 2
- 229960003438 aspartame Drugs 0.000 description 2
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 235000019219 chocolate Nutrition 0.000 description 2
- 229940059329 chondroitin sulfate Drugs 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- AVJBPWGFOQAPRH-FWMKGIEWSA-L dermatan sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 description 2
- 229940051593 dermatan sulfate Drugs 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000012407 engineering method Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 230000032050 esterification Effects 0.000 description 2
- 238000005886 esterification reaction Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 229960002442 glucosamine Drugs 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- UHUSDOQQWJGJQS-UHFFFAOYSA-N glycerol 1,2-dioctadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(CO)OC(=O)CCCCCCCCCCCCCCCCC UHUSDOQQWJGJQS-UHFFFAOYSA-N 0.000 description 2
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 2
- 239000001685 glycyrrhizic acid Substances 0.000 description 2
- 229960004949 glycyrrhizic acid Drugs 0.000 description 2
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 2
- 235000019410 glycyrrhizin Nutrition 0.000 description 2
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- KXCLCNHUUKTANI-RBIYJLQWSA-N keratan Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@H](COS(O)(=O)=O)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H]([C@@H](COS(O)(=O)=O)O[C@@H](O)[C@@H]3O)O)[C@H](NC(C)=O)[C@H]2O)COS(O)(=O)=O)O[C@H](COS(O)(=O)=O)[C@@H]1O KXCLCNHUUKTANI-RBIYJLQWSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 235000021110 pickles Nutrition 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 150000004804 polysaccharides Chemical class 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical class CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 150000003432 sterols Chemical class 0.000 description 2
- 235000003702 sterols Nutrition 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- FFJCNSLCJOQHKM-CLFAGFIQSA-N (z)-1-[(z)-octadec-9-enoxy]octadec-9-ene Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCCCCCCC\C=C/CCCCCCCC FFJCNSLCJOQHKM-CLFAGFIQSA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- AAHXURZWGMBVCT-UHFFFAOYSA-N 2-(3,4-dihydroxyphenyl)-3,7-dihydroxychromen-4-one Chemical compound C=1C(O)=CC=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1.C=1C(O)=CC=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 AAHXURZWGMBVCT-UHFFFAOYSA-N 0.000 description 1
- VOUAQYXWVJDEQY-QENPJCQMSA-N 33017-11-7 Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 VOUAQYXWVJDEQY-QENPJCQMSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000031295 Animal disease Diseases 0.000 description 1
- 235000003276 Apios tuberosa Nutrition 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000010744 Arachis villosulicarpa Nutrition 0.000 description 1
- 108010075254 C-Peptide Proteins 0.000 description 1
- 240000004160 Capsicum annuum Species 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 229920000832 Cutin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 208000018672 Dilatation Diseases 0.000 description 1
- 229920001875 Ebonite Polymers 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 238000009004 PCR Kit Methods 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108010050808 Procollagen Proteins 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 208000031737 Tissue Adhesions Diseases 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 235000020167 acidified milk Nutrition 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 235000008452 baby food Nutrition 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 235000013527 bean curd Nutrition 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- 206010061592 cardiac fibrillation Diseases 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008406 cosmetic ingredient Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 239000013530 defoamer Substances 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 229960005215 dichloroacetic acid Drugs 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000003721 exogen phase Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019985 fermented beverage Nutrition 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 230000002600 fibrillogenic effect Effects 0.000 description 1
- 230000003328 fibroblastic effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- SKIAPYSRYIZMNZ-UHFFFAOYSA-N formic acid;2-methylphenol Chemical class OC=O.CC1=CC=CC=C1O SKIAPYSRYIZMNZ-UHFFFAOYSA-N 0.000 description 1
- 230000007160 gastrointestinal dysfunction Effects 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- UQEAIHBTYFGYIE-UHFFFAOYSA-N hexamethyldisiloxane Chemical compound C[Si](C)(C)O[Si](C)(C)C UQEAIHBTYFGYIE-UHFFFAOYSA-N 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 230000027555 hydrotropism Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 235000013622 meat product Nutrition 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- CXQXSVUQTKDNFP-UHFFFAOYSA-N octamethyltrisiloxane Chemical compound C[Si](C)(C)O[Si](C)(C)O[Si](C)(C)C CXQXSVUQTKDNFP-UHFFFAOYSA-N 0.000 description 1
- KSCKTBJJRVPGKM-UHFFFAOYSA-N octan-1-olate;titanium(4+) Chemical compound [Ti+4].CCCCCCCC[O-].CCCCCCCC[O-].CCCCCCCC[O-].CCCCCCCC[O-] KSCKTBJJRVPGKM-UHFFFAOYSA-N 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000010773 plant oil Substances 0.000 description 1
- 239000012165 plant wax Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000223 polyglycerol Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 238000001226 reprecipitation Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 229940108325 retinyl palmitate Drugs 0.000 description 1
- 235000019172 retinyl palmitate Nutrition 0.000 description 1
- 239000011769 retinyl palmitate Substances 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- LUPNKHXLFSSUGS-UHFFFAOYSA-M sodium;2,2-dichloroacetate Chemical compound [Na+].[O-]C(=O)C(Cl)Cl LUPNKHXLFSSUGS-UHFFFAOYSA-M 0.000 description 1
- RRLOOYQHUHGIRJ-UHFFFAOYSA-M sodium;ethyl sulfate Chemical compound [Na+].CCOS([O-])(=O)=O RRLOOYQHUHGIRJ-UHFFFAOYSA-M 0.000 description 1
- NWZBFJYXRGSRGD-UHFFFAOYSA-M sodium;octadecyl sulfate Chemical compound [Na+].CCCCCCCCCCCCCCCCCCOS([O-])(=O)=O NWZBFJYXRGSRGD-UHFFFAOYSA-M 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000012177 spermaceti Substances 0.000 description 1
- 229940084106 spermaceti Drugs 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000013271 transdermal drug delivery Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 230000010148 water-pollination Effects 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Molecular Biology (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicinal Preparation (AREA)
Abstract
Composition the present invention relates to contain fisetin as active ingredient, the effect that composition of the invention has to be improved or prevention skin aging, wrinkle, flexibility decrease, moisture decline, specifically, by the synthesis for promoting collagen (type I) and sulfated glycosaminoglycans in skin, improve and prevent wrinkle, the effect of the decline such as aging, elastic of skin with essence, and, due to from natural materials, therefore, Side effect is low, can effectively be used as the active ingredient of cosmetics, pharmaceuticals or food etc..
Description
Technical field
The present invention relates to a kind of cosmetic for improving skin, health functional food and pharmaceutical composition.
Background technology
Skin is to undertake the vitals that bodily fuctions are protected from external environment condition.For example, carry the water for preventing inside
Point and barrier function from active ingredient to outside outflow and body heat regulation function, the different physiological roles such as excretory function.With individual
Body it is aging, skin also can lose critical function because aging.The reason for skin aging, can be roughly divided into：It is construed as the age
The internal cause sexual factor of growth；And, because of the external cause sexual factor of sun light injury etc..Due to this inside and outside factor, skin occurs old
Change, cause to generate wrinkle on skin and the phenomenon that elasticity is reduced occur, and this phenomenon is mainly the damage because of skin corium
Produced with change.
The structure of skin is broadly dassified into epidermis, skin corium, subcutaneous layer of fat.Skin corium is the reality for occupying skin 90%
The skin of matter, is made up of the matrix between connective tissue and tytosis and connective tissue such as collagenous fibres, elastomer.Glue
Fibrillation is generated by fibroblast, it is known that its main function is to assign the robustness of skin machinery, assigns connective tissue and supports
Drag and tissue adhesion, and worked in terms of the adhesion of support cell.This collagen its amount with age
Gradually decrease, and structural damage, and this phenomenon is considered as endogenous skin aging, is the main cause for producing wrinkle.Also,
The reason for exogen skin aging, generation wrinkle being can be regarded as because of the collagenous fibres damage of ultraviolet.Elastomer is used as guarantor
The important substance of skin elasticity is held, when it occurs modified because of a variety of causes, the decline of skin elasticity can be caused.Matrix is to fill out
The binding fiber and intercellular material of corium are filled, is existed with unbodied gel state.It is many as the hydrophily for constituting matrix
The glycosaminoglycan of sugar, it exists when being dissolved in water with viscous liquid state, therefore also referred to as mucopolysaccharide (mucopolysaccharide).
Glycosaminoglycan (Glycosaminoglycan；GAG) be disaccharides the structure that connects repeatedly of sugar, for example, having transparent
Matter acid (Hyaluronic acid), chondroitin sulfate (chondroitin sulfate), Heparan sulfate (heparan
Sulfate), heparin (heparin), keratan sulfate (keratan sulfate), dermatan sulfate (dermatan
sulfate).GAG can substantially be divided into two kinds, the i.e. GAG not comprising sulfate radical, such as hyaluronic acid (Hyaluronic acid)；
And the GAG comprising sulfate radical, as described above in remaining five kinds.
GAG is primarily present in extracellular matrix (Extracellular matrix in skin；ECM), filling is played to account for
According to ECM most collagenous fibres, elastomer between space effect, and perceive change or the cell of peripheral protein matter
Change, so as to transmit signal to cell.Thus, growth, differentiation and the normal function of cell are influenceed.Also, due to GAG with
The adhesion of hydrone is outstanding, therefore to keeping moisture of skin to also function to important effect.When due to internal cause, outer thus generation skin
When skin is aging, the GAG amounts being present in corium are reduced, and recombine the ability decline of GAG, so as to increase the sky of skin corium
Gap, the problems such as cause the generation of wrinkle, the reduction of skin elasticity and moisture to reduce.
At present, the prevention as the wrinkle used for improving this skin aging and wrinkle and improvement cosmetic
In, it is representative containing vitamin A (view alcohol) or the product of retinyl palmitate.However, the product containing these raw materials
Product process over time, not only the change to composition in product is fragile, also, when being impregnated with concentration more than valid density or
Decompose in skin, there is a problem that obvious skin irritatin and redness etc. can be caused, therefore, for safety, its usage amount is received
Limit, so that the prevention of wrinkle and improvement and moistening effect are substantially faint.
Therefore, to exploitation can neither trigger safety issue, additionally it is possible to improve the aging and moisturizing of skin material and
The demand of the cosmetic comprising the material exists always.
As described above, exist can either improve to essence skin aging and wrinkle, moisturizing energy to exploitation all the time
Power etc., and do not have the demand of virose age resister, in order to solve above-mentioned problem, the present inventor is old to that can suppress skin always
Change and material that wrinkle is produced studied, confirm fisetin to the synthesis of the sulfated glycosaminoglycans of Skin Cell and
The facilitation effect of the synthesis of collagen types I is outstanding, so as to complete the present invention.
The content of the invention
Therefore, it is an object of the present invention to provide cosmetic composition, pharmaceutical composition with skin improvement effects
And food compositions.
In order to reach above-mentioned problem, the present invention provides a kind of cosmetic composition, and it is yellow comprising paint as active ingredient
Plain (fisetin) or derivatives thereof.
Above-mentioned composition, can be for promoting sulfated glycosaminoglycans (sulfated Glycosaminoglycan) to close
Into composition.
Above-mentioned composition, can be the composition for promoting collagen synthesis.
Above-mentioned composition, can be for improving or preventing skin aging, wrinkle of skin, skin elasticity decline, skin water
Content is divided to decline or aging composition.
The content of the fisetin being included in above-mentioned composition can be 1 × 10 relative to total composition-5~10 weights
Amount %.
Above-mentioned cosmetic composition can have be selected from by solution, suspension, emulsion, paste, gel, creme,
Skin lotion, pulvis, soap agent, the cleaning agent containing surfactant, oil, vanishing cream, toner class, cosmetic ointment, spray, face
Formulation in the group that film, suncream, sun screen, makeup removing agent and cleaning agent are constituted.
In addition, the present invention provides a kind of cosmetics, it makees active ingredient, comprising fisetin (fisetin) or derivatives thereof.
In addition, the present invention provides a kind of pharmaceutical composition for preventing and treating skin injury disease, it is used as effective
Composition, comprising fisetin (fisetin) or derivatives thereof.
Above-mentioned skin injury disease, can be selected from by erythema (erythema), skin aging, wrinkle of skin, skin capillary
Blood vessel dilatation disease, skin elasticity decline and skin moisture content decline in constituted group.
Can be that aforementioned pharmaceutical compositions have selected from by ointment, creme, tablet, pill, pulvis, granule, glue
The use of the formulation in the group that wafer, oral solution, syrup, the aqueous solution, non-aqueous solvent, suspending agent and emulsion are constituted
In the composition of prevention and treatment skin injury disease.
In addition, the present invention provides a kind of health functional food composition, it includes fisetin as active ingredient
(fisetin) or derivatives thereof, and for improving or preventing skin aging, wrinkle of skin, skin elasticity to decline or moisture of skin
Content declines.
It is of the invention as active ingredient comprising fisetin composition, with improve or prevention the aging of skin, wrinkle,
The effect that flexibility decrease, moisture decline, specifically, by promoting collagen in skin (I types) and sulphation
The synthesis of glycosaminoglycan, it is possible to increase the mechanical robustness of skin, so as to have the essence ground to improve and prevention wrinkle of skin, old
The effect of the declines such as change, elasticity, also, because from natural materials, Side effect is few, therefore in cosmetic, medicine
It is highly useful in composition and food compositions.
Specific embodiment
The present invention relates to a kind of cosmetic composition, its as active ingredient, comprising fisetin or derivatives thereof.
Above-mentioned fisetin can be represented by following chemical formula 1.
Chemical formula 1：
The compound name of above-mentioned chemical formula 1 is 2- (3,4- dihydroxy phenyl) -3,7- dihydroxy chromone (2- (3,4-
Dihydroxyphenyl) -3,7-dihydroxychromen-4-one), general entitled fisetin (fisetin).
Above-mentioned fisetin is the one kind in flavonoids species, is that molecular formula is C15H10O6, molecular weight is 286 compound.
Above-mentioned fisetin is generally the crystallization of yellow needles, and fusing point is more than 360 DEG C, and the fisetin recrystallized in spirit of vinegar can contain
6 molecular crystalline water.
Above-mentioned fisetin, can be by chemical syntheses such as various organic chemistry procedures as known in the art.Furthermore it is possible to from
Extracted in plant extracts and refined, so as to be readily available.Fisetin of the invention, is from Sigma-Aldrich (Sigma
Aldrich, the U.S.) purchase use.
The derivative of above-mentioned fisetin, including fisetin part-structure is substituted or the compound that changes in, show
All compounds of the effect similar to the effect of fisetin of the present invention.Fisetin of the invention, can be used as active ingredient, should
For suppress, treat and improve with during collagen is reduced and the relevant wrinkle of flexibility decrease is produced, and, can be used as effective
Composition, is applied to suppress, treat and improve other constituents i.e. conjunction of sulfated glycosaminoglycans because of dermal extracellular matrix
It is during wrinkle is produced caused by declining and decomposing acceleration into amount also, also outstanding in the curative effect of the wound of skin etc. to occurring,
And hence it is also possible to be used as the active ingredient of treat wound.And then, even comprising a small amount of fisetin, it is also possible to keep
Outstanding effect, therefore in pharmaceuticals or cosmetics, it is old as improvement or prevention wrinkle of skin, skin elasticity decline or skin
The active ingredient of change, can be utilized with various formulations, so as to have the advantages that have a wide range of application.
Confirming above-mentioned fisetin can promote the biosynthesis of sulfated glycosaminoglycans and collagen types I, from
And can play makes the composition of collagen types I and dermis of skin extracellular matrix keep fine and close effect.
In a specific embodiment, in order to understand fisetin to HF and the effect of keratinocyte,
And when HF processes fisetin, the generation for having confirmed sulfated glycosaminoglycans and collagen types I increases
(Tables 1 and 2).Above-mentioned fisetin can promote the expression of HAS-2, HAS-3, in an embodiment of the present invention, in order to understand paint
The enhancing effect that flavine is expressed HAS-2, HAS-3, and Human keratinocytes process fisetin when, confirm HAS-2,
The expression of HAS-3 increases (table 3).
Therefore, cosmetic composition of the invention, can be for promoting sulfated glycosaminoglycans (sulfated
Glycosaminoglycan) the cosmetic composition of synthesis and/or collagen synthesis.
In addition, cosmetic composition of the invention can be the cosmetic composition of skin moisture-keeping.
Cosmetic composition comprising above-mentioned fisetin, plays the generation for improving sulfated glycosaminoglycans in skin,
And promote I collagen types albumen generation, enhancing HAS expression effect such that it is able to improve skin, it is therefore preferable that be for
Improve or prevention skin aging, wrinkle of skin, the cosmetic composition that skin elasticity declines or skin moisture content declines.
By experiment, confirm during using composition of the invention, skin moisture content increases and water holding capacity
Increase (table 4), also, by experiment, confirm the effect of improvement, pre- anti-aging, prevention or the improvement wrinkle of skin of skin elasticity
Really outstanding (table 5).
Above-mentioned term " skin aging ", refers to occur elasticity reduction, gloss reduction, wrinkle generation, power of regeneration on skin
Decrease or the seriously symptom such as dry, can induce, when same with collagen, elastin laminin because of the passage of time or external environment condition etc.
When the extracellular matrix such as sulfated glycosaminoglycans constituent when reducing, can produce that skin elasticity declines or wrinkle of skin is generated
Phenomenon, it is possible to induced because of the reduction of mentioned component.
Term " wrinkle of skin " of the invention, refers to the microgroove or fold (fold) being formed on skin.Above-mentioned skin wrinkle
Line can induce because of gene, the reduction of the collagen being present in dermis of skin, external environment condition etc., when contributing to elastin laminin
When sulfated glycosaminoglycans with the structural support in the cell such as collagen are reduced, wrinkle of skin can be produced.
Above-mentioned term " skin elasticity ", is the bullet being made up of the elastin laminin (elastin) by being present in skin corium
Property fiber produce, due to this elastomer as rubber with low-down coefficient of elasticity, therefore by small strength
Can easily deform, and can be resiled easily when above-mentioned strength is removed.Due to above-mentioned sulfated glycosaminoglycans
Reduction, can not only bring the reduction of collagen and elastin laminin, and be difficult to holding structure, therefore skin elasticity occurs
The situation of decline.
Above-mentioned term " moisturizing ", refers to suitably regulation moisture loss (moisture evaporation) etc., so as to keep the perseverance of organism
Perseverance.When with the sulfated glycosaminoglycans reduction simultaneously of hyaluronic acid in skin, moisture loss can be caused.
Above-mentioned term " prevention ", no matter referring to the reason for causing aging, suppresses or postpones skin using composition of the invention
The situation that skin is aging or wrinkle is generated, elasticity or moisture decline, preferably refers to be formed by fibroblast and cutin
Promote the effect of the biosynthesis of sulfated glycosaminoglycans and collagen types I in cell, reach the situation for suppressing or postponing.
Above-mentioned term " improvement ", refers to keep or reinforcing and wrinkle of skin, aging and elastic related ability, so that skin
Skin state takes a turn for the better or benefited all behaviors, specifically referring to the synthesis for promoting sulfated glycosaminoglycans, not only suppresses elastic egg
The reduction of white and collagen, also keeps their structure, so that wrinkle of skin, aging, elastic or moisture are obtained
Turn.
Fisetin can be included in above-mentioned composition with effective dose.
Above-mentioned term " effective dose ", is the phenomenon for referring to suppress or postpone skin aging or wrinkle generation, or can
The amount of the fisetin of the wrinkle that alleviation has been generated.
The effective dose of the above-mentioned fisetin being included in wrinkle improvement composition of the invention, can improve according to wrinkle
With the form of composite preparation, and the above-mentioned fisetin method for being used in skin and time for resting on skin etc. without
Together.For example, when above-mentioned wrinkle improvement composition is produced in the pharmaceuticals form of the wrinkle of skin generated in dermatological treatment
During product, compared with the form of the daily cosmetics suitable for skin by the situation of commercialization, the paint of higher concentration can be included
Flavine.Also, in the case of in the form of the cosmetics by commercialization, the makeup removing of skin is stayed in when the active ingredient short time
In the case that agent, cleaning agent etc. rinse the cosmetics of (wash-off) type, the fisetin of higher concentration can be included.Conversely,
When the cosmetic for staying in disposable (leave-on) type such as toner, emulsion, frost, the essence of skin for a long time for active ingredient
In the case of product, the fisetin of low concentration can be included compared with the cosmetics of type of flush.
Specifically, the content of the fisetin being included in above-mentioned composition, relative to total composition can for 1 ×
10-5~10 weight %, or 1 × 10-4~8 weight %, or 1 × 10-3~6 weight %, or 1 × 10-2~5 weight %, or 0.05~
4 weight %, or 0.01~2 weight %.When the content of mentioned component is less than 0.00001 weight %, it is difficult to obtain its effect, and
When more than 10 weight %, then as solvent the composition such as dissolubility overall processing reduction, accordingly, as described laterization
The use of the various uses such as cosmetic formulation may be limited.
In addition, the concentration of the fisetin in being included in above-mentioned composition, preferably 0.1 μ g/mL~100 μ g/mL, more preferably
It is 1 μ g/mL~50 μ g/mL, more preferably 5 μ g/mL~25 μ g/mL.
Above-mentioned cosmetic composition can be used with any formulation suitable for epidermis.For example, can have be selected from by
Solution, suspension, emulsion, paste, gel, creme, skin lotion, pulvis, soap agent, the cleaning agent containing surfactant, oil, powder
In the group that cream base, toner class, cosmetic ointment, spray, facial mask, suncream, sun screen, makeup removing agent and cleaning agent are constituted
Formulation, but it is not limited to above-mentioned concrete example.
In addition, above-mentioned cosmetic composition can be as strengthening skin elasticity, preventing skin aging, improvement skin
The skin preparations for extenal use of wrinkle etc. and use.
In one embodiment of this invention, fisetin is manufactured into externally-applied ointment or essence formulation, and is applied to
During the skin of people, confirm that there is outstanding wrinkle of skin improvement.Especially, confirm in the present invention, even if with low dense
Degree is i.e. a small amount of using in the case of fisetin, it is also possible to show outstanding effect improving wrinkles.
For the ease of using and processing, the cosmetic composition containing fisetin of the invention can also be comprising cosmetic
Acceptable carrier on, diluent, auxiliary agent, colouring agent, stabilizer, fragrant agent, surfactant, oil, NMF, alcohol,
Thickener, antioxidant, pH adjusting agent, sun-screening agent etc., when being used as composition for external application, additionally it is possible to liquid, breast
Any formulation that shape, white shape, ointment, bar-shaped, facial mask, paste, pulvis etc. can be applied to epidermis is used.
For the ease of using and processing, above-mentioned cosmetic composition can also learn upper acceptable figuration comprising making up
Agent.As the upper acceptable excipient of above-mentioned cosmetic, can enumerate surfactant, emulsifying agent, soap acid, solvent, adhesive,
Diluent, lubricant, stabilizer, spices, water, lower alcohol, thickener, chelating agent, pigment, preservative, colouring agent, preservative agent,
It is antibiotic, antioxidant, defoamer, antiseptic, anti-reprecipitation agent, enzyme, plant or mineral oil, fat, fluorescent material, antifungal
It is agent, hydrotropism's inducing substance, NMF, aromatic, aroma carrier, protein, organosilicon, solubilizer, sugar derivatives, sun-proof
Agent, vitamin, plant extracts or wax etc., and can comprising it is therein one or more.
When above-mentioned cosmetic combination dosage form is turned into cosmetics, the carrier function for playing active component can be included
The acceptable known excipient of skin, specifically may be referred to International cosmetic ingredient
Dictionary, 6th ed., The cosmetic, Toiletry and Fragrance Association, Inc.,
Washington, the content disclosed in 1995.By above-mentioned document as part of this specification.
Moreover, it relates to a kind of cosmetics, its as active ingredient, comprising fisetin or derivatives thereof.
Above-mentioned cosmetics can have selected from by toner class, essence class, surfactant class, skin lotion class, white class, face
Any one formulation in the group that film class is constituted.
For example, above-mentioned cosmetics can be surfactant, smoothing toner, toner, astringent lotion, skin lotion, emulsion, skin-moisturizing, skin
Liquid, nutrition skin lotion, massage cream, nourishing cream, moisturiser, hand lotion, vanishing cream, essence, nutrition essence, facial mask, soap,
Mildy wash, clean skin dew, makeup removing frost, body lotion and shower cream etc., but it is not limited to this.
Moreover, it relates to a kind of pharmaceutical composition for preventing or treating skin injury disease, it is used as effective
Composition, comprising fisetin or derivatives thereof.
Moreover, it relates to a kind of pharmaceuticals comprising aforementioned pharmaceutical compositions or medical auxiliary product (sanitary
aid)。
Aforementioned pharmaceutical compositions, refer to for the purpose of diagnosing, treat, mitigate, dispose or prevention includes the Animal diseases of people
And the medicinal material for using.
Above-mentioned skin injury disease, refers to the disease occurred by skin damage, specifically, be can be selected from by erythema
(erythema), skin aging, wrinkle of skin, skin capillary vascular expansion disease, skin elasticity decline, skin moisture content decline
And in aging constituted group.
The preferred dosage of pharmaceutical composition of the invention, age, sex according to administration object, body weight, symptom, disease
Without same during degree, drug form, method of administration and the administration of disease, those skilled in the art can properly select.In order to
Outstanding effect is obtained, preferably pharmaceutical composition of the invention was administered with the amount of 0.01~1000mg/ days.Administration can be daily
Once, it is also possible to carry out several times.In addition, dosage can be entered according to age, sex, body weight, the degree of disease, method of administration etc.
Row increase and decrease.Therefore, above-mentioned dosage does not limit the scope of the present invention in any way.
Above-mentioned composition can be delivered medicine to by the lactations such as rat, mouse, domestic animal, people by the number of ways such as parenteral, oral
Animal, all modes of administration can be it is contemplated that for example, can be by oral, rectum or vein, muscle, subcutaneous, intrauterine
(intracerebroventricular) injection is administered in film or telocoele.
Pharmaceutical composition for preventing or treating skin injury disease of the invention, can individually comprising as effectively into
The above-mentioned fisetin for dividing, in addition, according to formulation, application method and application target, can also include pharmaceutically acceptable
Carrier, excipient, diluent and/or auxiliary element.
More specifically, in addition to above-mentioned active ingredient, can also comprising nutritional agents, vitamin, electrolyte, flavouring agent,
Colouring agent, hardening agent (enhancer), pectic acid and its salt, alginic acid and its salt, organic acid, protective colloid thickener, pH are adjusted
Section agent, stabilizer, preservative, glycerine, alcohol, the carbonating agent etc. for soda.
Above-mentioned " pharmaceutically acceptable ", refers to acceptable in a physiologically, and when being administered to animal, preferred pair people, generally
The allergic reactions such as gastrointestinal dysfunction, dizziness or reaction similarly will not be caused.Above-mentioned pharmaceutically effective amount, can basis
Suitably change during disease and its order of severity, patient age, body weight, health status, sex, method of administration and treatment etc..
As the example of above-mentioned pharmaceutically acceptable carrier, excipient or diluent, can enumerate selected from by lactose,
Glucose, sucrose, D-sorbite, mannitol, xylitol, antierythrite, maltitol, starch, gum arabic, alginates,
Gelatin, calcium phosphate, calcium silicates, cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxy benzene
Formates, the third hydroxy benzoate, talcum, magnesium stearate and mineral oil, dextrin, calcium carbonate, propane diols, atoleine and physiology
One or more of group that salt solution is constituted, but this is not limited to, common carrier, excipient or diluent can make
With.
Mentioned component can be added in the above-mentioned fisetin as active ingredient afterwards alone or in combination.
The formulation of aforementioned pharmaceutical compositions can be different according to application method, it is possible to use known in art of the present invention
Method carry out formulation, with after being administered to mammal, using the teaching of the invention it is possible to provide active component it is rapid, continue or postpone release
Put.As the example of above-mentioned formulation, can enumerate selected from by ointment, creme, tablet, pill, pulvis, granule, capsule,
Formulation in the group that oral solution, syrup, the aqueous solution, non-aqueous solvent, suspending agent and emulsion are constituted.
For above-mentioned formulation, excipient can also be included, for example, comprising conventional filler, increment drug, adhesive, collapsing
Solution agent, surfactant, anti-coagulants, lubricant, wetting agent, spices, emulsifying agent, preservative, sweetener, aromatic or preservative agent
Deng.
The solid pharmaceutical preparation being administered orally is commonly used for, comprising tablet (TABLETS), soft or hard rubber wafer
(CAPSULES), pill (PILLS), pulvis (POWDERS) and granule (GRANULES) etc., this preparation can mix one kind
More than excipient and modulate, for example, mixing starch, calcium carbonate (calcium carbonate), sucrose (sucrose) or breast
Sugared (lactose), gelatin etc..In addition, in addition to simple excipient, the lubricants such as magnesium stearate, talcum can also be used.
In addition, for the liquid preparation being administered orally, there is suspending agent (SUSTESIONS), oral solution, emulsion
(EMULSIONS) and syrup (SYRUPS) etc., in addition to water or atoleine as usually used simple diluent, also
Various excipient can be included, for example, wetting agent, sweetener, aromatic, preservative agent etc..
In the example of cutaneous penetration, have and be adapted to generation talcum powder, emulsion, suspension, oil, spray, ointment, soft containing fat
Cream (greasy ointment), cream ointment, gel, foaming agent or solution, and suitable for transdermal drug delivery system (TTS:
Transdermal therapeuticsystem) carrier and/or excipient.Topical pharmaceutical formulations of the invention, Ke Yishi
Semi-solid formulation, particularly, there is ointment (solution ointment, suspension ointment), creme, gel or paste.It is main in emulsus
What is used has：Fatty alcohol, for example, laruyl alcohol, cetanol, stearyl alcohol；Aliphatic acid, for example, palmitic acid or stearic acid；Liquid is solid
Body paraffin or ceresine, liquid to solid-like wax, for example, isopropyl myristate；Natural fat or partially synthetic fat, for example,
The ester of coconut fatty acid three；Fixed oil, for example, hydrogenated groundnut or castor oil；Or, the part esterification of glycerine fatty acid
Material, for example, glycerin monostearate or distearin.As preferred emulsifying agent, there is surfactant, can lift
Go out nonionic surfactant：The fatty acid ester of polyalcohol or its ethylene oxide adduct, for example, aliphatic acid polyglycerol esters or poly-
Ethylene oxide sorbitan fatty acid ester；Sorbitan fatty acid ester, for example, sorbitan monooleate and/or dehydration
Sorbierite isostearate etc., isostearate, sterol, polyoxyethylene aliphatic alcohol ether or fatty acid ester, anionic surface are lived
Property agent：The alkali metal salt of fatty alcohol sulfonates, for example, NaLS, cetanol sodium sulfovinate or sodium stearyl sulfate,
These are typically in the presence of above-mentioned fatty alcohol, for example, being used in the presence of cetanol or stearyl alcohol.Wherein, particularly,
To can be used to prevent the dry preparation of creme, for example, being that glycerine, D-sorbite, propane diols and/or polyethylene glycol add by polyalcohol
It is added in water phase, or, in preservative agent, spices etc. being made an addition into water phase.
Pharmaceutical preparation of the invention can be the ointment of anhydrous state.In addition, said medicine preparation can be local comprising being adapted to
Purposes and under body temperature for liquid paraffin, particularly, low viscosity paraffin can be included.Or, said medicine preparation can be wrapped
Containing natural fat or partially synthetic fat (for example, the ester of coconut fatty acid three), fixed oil is (for example, hydrogenated groundnut or castor
Sesame oil), the material (for example, glycerin monostearate and distearin) of the fatty acid part esterification of glycerine, organosilicon
(for example, polymethyl siloxane, such as HMDO or octamethyltrisiloxane).In addition, said medicine preparation, for example also
Comprising relevant with aqueous creams, and the fatty alcohol of moisture absorption amount can be improved, and sterol, lanocerin (wool wax),
Other emulsifying agents and/or other additives.
In the present invention, when aforementioned pharmaceutical compositions formulation is turned into pharmaceuticals, Remington ' s are referred to
Content disclosed in Pharmaceutical Science, Mack Publishing Company, Easton PA, and will be above-mentioned
Document as part of this specification.
In addition, for improvement, mitigation, treatment or the prevention of skin injury disease, can be used alone medicine group of the invention
Compound, or can be by pharmaceutical composition of the invention and operation, hormone therapy, drug therapy and use BRM
Method is used in combination.
More than, unless illustrated in this manual, the numerical value described in this specification includes the scope impartial with it.
Moreover, it relates to health functional food composition, it contains fisetin or derivatives thereof as active ingredient,
And skin aging, wrinkle of skin, skin elasticity decline or skin moisture content declines for improving or preventing.
Above-mentioned food, refers to the natural materials containing more than one nutrients or processing material, preferably refers to by certain
The direct-edible state of the operation of degree, including common health functional food, functional food, beverage, food additives,
And beverage additive.
Above-mentioned food, for example, can be various foodstuffs, beverage, chewing gum class, tea, B B-complex, healthcare function food
Product etc..And, in the present invention, food is also including food of special nutrients (for example, the newborn class of modulation, infant food etc.), meat
Processed goods, processed fish meat products, Tofu, bean jelly class, noodles (for example, hand-pulled noodles class, such as noodles etc.), health care accesary foods, seasoning food
Product (for example, soy sauce, salty sauce, thick chilli sauce, mixing sauce etc.), sauce class, Biscuits (for example, snack categories), newborn processed goods (for example,
Acidified milk, cheese etc.), other processed foods, pickles, cure foods (various pickles classes, sauced class etc.), beverage is (for example, fruit
With greengrocery beverage, soya-bean milk class, fermented beverage class etc.), natural flavouring (for example, hand-pulled noodles soup etc.), but it is not limited to this.
Above-mentioned food, functional food, health functional food, beverage, food additives and beverage additive, can pass through
Conventional manufacture method manufacture.
" health functional food " in the present invention, refers to by physics, biological, biological engineering method etc., to food
Product impart added value, so as to the function of the food, the food group of specific purpose is expressed in, or, refer to by setting
Meter processing, make that food composition has prevents with organism defence tempo adjustment, disease and the relevant body regulation such as recovers
Function, gives full expression to the food in organism.
Above-mentioned health functional food, be able to can also include usual comprising acceptable food auxiliary additive in bromatology
Suitable carrier, excipient and the diluent used in the manufacture of health functional food.
Beverage of the invention, refers to the general designation of the material drunk to quenching one's thirst or sample, including health functional beverage.
Above-mentioned beverage, except as must composition above-mentioned fisetin (fisetin) or its derivative are included with the ratio that specifies
Beyond thing is as active ingredient, do not have special restriction to other compositions, also, identical with common beverage, may be used also
Comprising the other compositions such as various flavouring agents or natural carbohydrate.
As above-mentioned natural carbohydrate, the disaccharides of the monose of glucose, fructose etc., maltose, sucrose etc. can be enumerated,
The polysaccharide of dextrin, cyclodextrin etc., or xylitol, D-sorbite, antierythrite etc. sugar alcohol etc..Above-mentioned flavouring agent, can be as
The natural flavours such as the qualities of stevia extract of Talin, rebaudioside A (Rebaudioside-A) or glycyrrhizic acid, or, can be with
It is the synthesis flavouring agent of essence, Aspartame etc..
The addition of above-mentioned natural carbohydrate relative to food compositions 100mL of the invention ordinarily be about 1g~
20g, preferably 5g~12g.In addition, composition of the invention can also be containing for manufacturing fruit juice, fruit drink, vegetables
The pulp of beverage.
Apart from the above, food compositions of the invention can include various nutritional agents, vitamin, mineral matter (electrolyte),
Synthesis flavouring agent and the natural flavour mountaineous dose of flavouring agent of grade, colouring agent and hardening agent (cheese, chocolate etc.), pectic acid and its salt,
Alginic acid and its salt, organic acid, protective colloid thickener, pH adjusting agent, stabilizer, preservative, glycerine, alcohol, in soda
Carbonating agent for using etc..
These compositions may be used alone or in combination and use.The ratio of above-mentioned additive is unimportant, can be relative to this hair
Bright fisetin (fisetin) or derivatives thereof 100 weight portions are to be selected in the range of 0~2000 weight portion.
Above-mentioned " health functional beverage ", refers to, by physics, biological, biological engineering method etc., beverage to be assigned
Added value, so as to the function of the beverage, be expressed in the beverage group of specific purpose, or, refer to be processed by designing,
Make beverage constitute have the relevant body regulatory function such as prevent and recover with organism defence tempo adjustment, disease, fill
Divide the beverage for being expressed in organism.
Above-mentioned health functional beverage, except as must composition with the ratio that specifies comprising fisetin of the invention as
Beyond active ingredient, do not have special restriction to other compositions, identically with common beverage, can also include various fragrance
The other compositions such as agent or natural carbohydrate
As above-mentioned natural carbohydrate, the disaccharides of the monose of glucose, fructose etc., maltose, sucrose etc. can be enumerated,
The polysaccharide of dextrin, cyclodextrin etc., or xylitol, D-sorbite, antierythrite etc. sugar alcohol etc..Above-mentioned flavouring agent, can be as
The natural flavours such as the qualities of stevia extract of Talin, rebaudioside A (RebaudiosideA) or glycyrrhizic acid, or, Ke Yishi
The synthesis flavouring agent of essence, Aspartame etc..
The addition of above-mentioned natural carbohydrate relative to food compositions 100mL of the invention ordinarily be about 1g~
20g, preferably 5g~12g.In addition, composition of the invention can also be containing for manufacturing fruit juice, fruit drink, vegetables
The pulp of beverage.
Apart from the above, food compositions of the invention can include various nutritional agents, vitamin, mineral matter (electrolyte),
Synthesis flavouring agent and the natural flavour mountaineous dose of flavouring agent of grade, colouring agent and hardening agent (cheese, chocolate etc.), pectic acid and its salt,
Alginic acid and its salt, organic acid, protective colloid thickener, pH adjusting agent, stabilizer, preservative, glycerine, alcohol, in soda
Carbonating agent for using etc..These compositions may be used alone or in combination and use.The ratio of above-mentioned additive is unimportant, can be in phase
It is to be selected in the range of 0~20 weight portion for the weight portion of fisetin of the invention 100.
Above-mentioned health functional food can also include food additives, if suitable as food additives, without it
In the case that he specifies, then according to the food additives code general provisions and ordinary test side ratified by food pharmaceuticals State Security Department
Method etc., and specification and standard based on relevant classification judged.
During health functional food of the invention is manufactured, can as needed, suitably increase and decrease is including including beverage
Food in the fisetin of the present invention (fisetin) that is added or derivatives thereof content, preferably its usage amount is relative to food
The weight % of total amount 100 is 0.00001~10 weight %.
Moreover, it relates to use of the fisetin in above-mentioned cosmetic, pharmaceutical composition or food compositions are manufactured
On the way, the method for further relating to improve skin, the method includes the step of fisetin of effective dose is applied to skin or is taken.
Below, for the ease of understanding the present invention, preferred embodiment is enumerated.But, following embodiments are merely to more hold
Change places and understand the present invention and provide, present disclosure is not limited to following embodiments.
Embodiment 1：Confirm the synthetic effect of promotion collagen types I in HF
During fisetin made an addition into the nutrient solution of HF (Human fibroblast), on a cellular level really
Accept and promote the synthetic effect of collagen.The fisetin for being used, is from Sigma-Aldrich (Sigma Aldrich, U.S.
State) buy and use.It is using PICP EIA kits (Procollagen Type to the measure of synthesized collagen
I C-Peptide Enzyme Immuno Assay KIT) quantified.
In an experiment, the ultimate density of fisetin is adjusted to 10 μ g/mL, 20 μ g/mL.By fisetin addition in people into fibre
After tieing up in the culture medium (DMEM culture mediums) of cell culture 48 hours, take nutrient solution, by PICP EIA kits, and using point
Light photometer, determines the collagen synthesis degree in each concentration respectively at 450 nm.
For comparative effectiveness, to fibroblastic culture medium (control group) and ultimate density without any material of addition
The mode for reaching 10ng/mL adds the sample of TGF-beta, and the synthesis degree of collagen is determined by identical method.
The increment rate of collagen generation, is calculated relative to the relative ratios of control group with collagen growing amount,
In showing the result in table 1 below.
Table 1
Embodiment 2：Confirm the effect for promoting sulfated glycosaminoglycans to synthesize in HF
During fisetin made an addition into the nutrient solution of HF (Human fibroblast), on a cellular level really
Accept and promote sulfated glycosaminoglycans synthetic effect.To the measure of sulfated glycosaminoglycans, detected using aminopolysaccharide sulfate
Kit (Blyscan glycosaminoglycan assay kit, Biocolor) is quantified.
In an experiment, the ultimate density of fisetin is adjusted to 1 μ g/mL, 10 μ g/mL, 20 μ g/mL.Fisetin is added
After being cultivated 24 hours in the culture medium (DMEM culture mediums) of HF, nutrient solution is taken, examined by aminopolysaccharide sulfate
Test agent box, and spectrophotometer is utilized, sulfated glycosaminoglycans total amount in determining each concentration respectively under 656nm.
The increment rate of sulfated glycosaminoglycans generation, is any relative to without addition with sulfated glycosaminoglycans growing amount
The relative ratios of the fibroblast culture medium (control group) of material calculate, in showing the result in table 2 below.
Table 2
As above-mentioned table 2 is represented, compared with the control group of untreated fisetin, confirm in 10 μ g/mL and 20 μ g/mL,
There is outstanding sulfated glycosaminoglycans synthetic effect respectively.
Embodiment 3：The increasing of hyaluronic acid synthetase (HAS) gene expression based on fisetin in Human keratinocytes
Plus
By Human keratinocytes in the DMEM culture mediums comprising 10% cow's serum (fetal bovin serum) with 1
×106Cell/mL is cultivated, and is injected separately into 6 orifice plates, is 3000 μ L per hole injection rate, has been cultivated 18 hours.Then,
Washed 2 times with the DMEM culture mediums not comprising cow's serum, processed 24 hours with fisetin (1ppm or 10ppm).Cell is reclaimed, is led to
After crossing RNeasy mini kits (Qiagen) extraction wholes RNA, quantified, the RNA of 1 μ g is utilized
RNA PCR kits (Applied Biosystems) carry out reverse transcription (reverse transcription).Reverse transcription reaction
It is to pass throughPCR instrument device (Biorad) is carried out.
Then, using the μ L of reverse transcription reaction solution 2 and HAS-2, HAS-3, GAPDH (glyceraldehyde 3-phosphate dehydro-genase,
Glyceraldehyde-3-phosphate dehydrogenase)Probe (Invitrogen, the U.S.,
HS02511055_S1, HS03929097_g1), carry out real-time fluorescence quantitative PCR (quantitative real time
PCR).Real-time fluorescence quantitative PCR, is using CFX 96touchTMReal-time fluorescent quantitative PCR detection system instrument (CFX96
TouchTMReal-Time PCR Detection System, Biorad) carry out.The experiment obtained by real-time fluorescence quantitative PCR
As a result, be on the basis of GAPDH as special (housekeeping) gene, by Livak K.J. it is outer (Methods,
2001,25,402-408) method described in is calculated.
In addition, as positive controls, in the group processed instead of above-mentioned fisetin with glucosamine 100ppm,
Confirm mrna expression amount.To the above results, on the basis of the mrna expression amount of negative control group for not carrying out any treatment
(100%), the mrna expression amount that fisetin processes experimental group and positive controls is quantized, and is shown in Table 3.
Table 3
As described in above-mentioned table 3, processed by fisetin, the expression of hyaluronic acid synthetase increases in Human keratinocytes
Plus, especially, the expression of HAS-2 and HAS-3 increases.In addition, it is thus identified that be less than 100 times than positive controls (glucosamine)
It is a small amount of using the expression quantity in the case of fisetin, also showing the HAS-2 similar to positive controls and HAS-3, with
When a small amount of less than 10 times uses, then confirm that the expression higher than positive controls can be induced.Thus, it is possible to confirm, even if
Lead to too small amount of fisetin, it is also possible to there is outstanding moistening effect to the reduction of moisture of skin maintenance dose.
Production Example 1 and comparative example 1：The manufacture of external ointment for skin
According to the composition of table 4 below, manufactured fisetin as outside the skin that active ingredient is included by conventional method
Use ointment.In addition, as comparative example 1, using the other compositions in addition to active ingredient, having manufactured external ointment for skin.
Table 4
| Composition (weight %) | Production Example 1 (weight %) | Comparative example 1 (weight %) |
| Fisetin | 0.2 | 0 |
| Diethyl sebacate | 8 | 8 |
| Spermaceti | 5 | 5 |
| Polyoxyethylene oleyl ether phosphate | 6 | 6 |
| Sodium Benzoate | 1 | 1 |
| Vaseline | To 100 | To 100 |
Production Example 2 and comparative example 2：The manufacture of essence
Used as Production Example 2, manufactured prevents skin aging with improvement wrinkle using fisetin as what active ingredient was included
Cosmetic essence formulation, in addition, as comparative example 2, using the other compositions in addition to active ingredient, with Production Example 2
Cosmetic essence has been manufactured in the same manner.Detailed composition is shown in table 5 below.
Table 5
| Composition (weight %) | Production Example 2 (weight %) | Comparative example 2 (weight %) |
| Fisetin | 0.5 | 0 |
| Glycerine | 10.0 | 10.0 |
| Aqueous solution of sodium hyaluronate (1%) | 5.0 | 5.0 |
| Crodaret | 1.0 | 1.0 |
| Methyl p-hydroxybenzoate | 0.1 | 0.1 |
| Spices | 0.05 | 0.05 |
| Pure water | To 100 | To 100 |
Experimental example 1：Wrinkle of skin improvement is confirmed by panel test (panel test)
It is object with the healthy women of 35 years old~50 years old for above-mentioned Production Example 2 and the essence of comparative example 2, following institute
Test wrinkle of skin improvement with stating.
The women 30 of 35 years old~50 years old is divided into two groups, every group 15, to one of which, is painted with comprising 0.5 weight %
The essence of the Production Example 2 of flavine smears face once daily, and smears three months, and another group then with the essence of comparative example 2
Smear face once daily, and smear three months.After three months, by the survey to testee, skin wrinkle is have rated
The improvement degree of line.In the survey of testee, compared with before use, wrinkle of skin is improved and elasticity raising is commented
Valency be without improving, the slightly three phases that improve, greatly improve, and the results are shown in table 6 below.
As above-mentioned table 6 is represented, in the case of the essence of Production Example 2 of the use comprising 0.5% fisetin, with use not
The situation of the essence of the comparative example 2 comprising fisetin is compared, and is able to confirm that the improvement of wrinkle of skin is more excellent.
Table 6
| Distinguish (name) | Without improvement | Slightly improve | Greatly improve |
| Production Example 2 | 1 | 7 | 7 |
| Comparative example 2 | 9 | 4 | 2 |
Experimental example 2：The effect improving wrinkles experiment of the cosmetic essence carried out by graphical analysis
By graphical analysis, the effect improving wrinkles of the essence of above-mentioned Production Example 2 and comparative example 2 are have rated.
Specifically, before on-test, the copy of side skin under collection (Xantopren, Bayer) eyes
(replica), after off-test, the same position below eyes gathers copy immediately, by graphical analysis, to wrinkle of skin
Two-dimension analysis has been carried out, the density of wrinkle of skin has been determined.The slip of the wrinkle of skin density based on graphical analysis, is to use essence
The wrinkle of skin density of Hua Suhou relative to the average value using the ratio between the wrinkle of skin density before essence, by said determination
Result is shown in table 7 below.
Table 7
| Wrinkle of skin density slip (%) | |
| Comparative example 2 | 14 |
| Production Example 2 | 56 |
Knowable to above-mentioned table 7, in the case of using the essence of the Production Example 2 comprising fisetin, and using being provided without
The situation of the essence of the comparative example 2 of fisetin is compared, and wrinkle of skin improvement is more excellent.In addition, in above-mentioned process of the test
In, do not find the stimulation or side effect of the essence to skin of Production Example 2.
Claims (11)
1. a kind of cosmetic composition, wherein, as active ingredient, comprising fisetin or derivatives thereof.
2. cosmetic composition according to claim 1, wherein, above-mentioned composition is for promoting sulphation osamine to gather
The composition of sugar synthesis.
3. cosmetic composition according to claim 1, wherein, above-mentioned composition is for promoting collagen synthesis
Composition.
4. cosmetic composition according to claim 1, wherein, above-mentioned composition is old for improving or preventing skin
Change, wrinkle of skin, the composition that skin elasticity declines or skin moisture content declines.
5. cosmetic composition according to claim 1, wherein, the content of above-mentioned fisetin is relative to total composition
It is 1 × 10-5~10 weight %.
6. the cosmetic composition according to any one of Claims 1 to 5, wherein, above-mentioned cosmetic composition tool
Have selected from by solution, suspension, emulsion, paste, gel, creme, skin lotion, pulvis, soap agent, containing the clear of surfactant
Lotion, oil, vanishing cream, toner class, cosmetic ointment, spray, facial mask, suncream, sun screen, makeup removing agent and cleaning agent institute
Formulation in the group of composition.
7. a kind of cosmetics, wherein, as active ingredient, contain fisetin or derivatives thereof.
8. a kind of pharmaceutical composition for preventing and treating skin injury disease, wherein, as active ingredient, contain fisetin
Or derivatives thereof.
9. pharmaceutical composition according to claim 8, wherein, above-mentioned skin injury disease is selected from old by erythema, skin
Change, wrinkle of skin, skin capillary vascular expansion disease, skin elasticity decline and skin moisture content decline in constituted group.
10. pharmaceutical composition according to claim 8, wherein, aforementioned pharmaceutical compositions have and are selected from by ointment, frost
Agent, tablet, pill, pulvis, granule, capsule, oral solution, syrup, the aqueous solution, non-aqueous solvent, suspending agent with
And the formulation in the group that is constituted of emulsion.
A kind of 11. health functional food compositions, wherein, contain fisetin or derivatives thereof as active ingredient, and for changing
Kind or prevention skin aging, wrinkle of skin, skin elasticity decline, skin moisture content declines or aging.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020150173774A KR102139659B1 (en) | 2015-12-08 | 2015-12-08 | Composition for improving the skin |
| KR10-2015-0173774 | 2015-12-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106852725A true CN106852725A (en) | 2017-06-16 |
Family
ID=59058925
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611106057.5A Pending CN106852725A (en) | 2015-12-08 | 2016-12-06 | Composition for improving skin |
Country Status (3)
| Country | Link |
|---|---|
| JP (2) | JP2017105777A (en) |
| KR (1) | KR102139659B1 (en) |
| CN (1) | CN106852725A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110392566A (en) * | 2018-02-23 | 2019-10-29 | 株式会社 Lg 生活健康 | Wrinkle-improving composition comprising skatole extract or its fraction as active ingredient |
| CN111012687A (en) * | 2019-12-31 | 2020-04-17 | 中山大学新华学院 | Compound fisetin microemulsion gel and preparation method and application thereof |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2018207952A1 (en) * | 2017-05-12 | 2020-04-16 | 国立大学法人九州大学 | Hair growth and / or hair growth composition |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009073488A1 (en) * | 2007-11-29 | 2009-06-11 | Smith Walter P | Methods and compositions for reducing facial lines and wrinkles |
| CN104262310A (en) * | 2014-08-27 | 2015-01-07 | 中国林业科学研究院林产化学工业研究所 | Preparation method of fisetin capable of inhibiting tyrosinase activity through rapid separation in medium-pressure column |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS55111411A (en) * | 1979-02-19 | 1980-08-28 | Sansho Seiyaku Kk | Cosmetic for making fair skin |
| JPS615016A (en) * | 1984-06-15 | 1986-01-10 | Dai Ichi Seiyaku Co Ltd | Remover for active oxygen |
| JP2001114686A (en) * | 1999-10-15 | 2001-04-24 | Sunstar Inc | Th2 CYTOKININ EXPRESSION SUPPRESSANT |
| US20070003536A1 (en) * | 2000-11-21 | 2007-01-04 | Zimmerman Amy C | Topical skin compositions, their preparation, and their use |
| JP2007161681A (en) * | 2005-12-16 | 2007-06-28 | Mitsui Chemicals Inc | Agent for preventing wrinkle and improving skin condition |
| JP5008168B2 (en) * | 2006-02-21 | 2012-08-22 | 丸善製薬株式会社 | Anti-aging agent and skin cosmetics |
| JP5226200B2 (en) * | 2006-10-16 | 2013-07-03 | 株式会社コーセー | Sulfated glycosaminoglycan production promoter and skin external preparation containing the same |
| JP2010138147A (en) * | 2008-12-15 | 2010-06-24 | Op Bio Factory Co Ltd | Melanogenesis inhibitor, antioxidant, anti-inflammatory agent, external preparation for skin, and food and beverage |
| JP5769387B2 (en) * | 2010-06-28 | 2015-08-26 | 国立研究開発法人医薬基盤・健康・栄養研究所 | Melanin production promoter |
| WO2014042261A1 (en) * | 2012-09-13 | 2014-03-20 | 森下仁丹株式会社 | Sirtuin gene potentiator, and pharmaceutical product, cosmetic product, and food product using same |
| KR20150019678A (en) * | 2013-08-14 | 2015-02-25 | 주식회사 엘지생활건강 | Composition for skin whitening |
| KR20160019768A (en) * | 2014-08-12 | 2016-02-22 | 주식회사 엘지생활건강 | Cosmetic or pharmaceutical composition for skin elasticity, anti-wrinkle, or skin moisturizing comprising Fisetin or a pharmaceutically acceptable salt thereof |
-
2015
- 2015-12-08 KR KR1020150173774A patent/KR102139659B1/en active IP Right Grant
-
2016
- 2016-12-06 CN CN201611106057.5A patent/CN106852725A/en active Pending
- 2016-12-07 JP JP2016237377A patent/JP2017105777A/en active Pending
-
2018
- 2018-12-06 JP JP2018229007A patent/JP2019059761A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009073488A1 (en) * | 2007-11-29 | 2009-06-11 | Smith Walter P | Methods and compositions for reducing facial lines and wrinkles |
| CN104262310A (en) * | 2014-08-27 | 2015-01-07 | 中国林业科学研究院林产化学工业研究所 | Preparation method of fisetin capable of inhibiting tyrosinase activity through rapid separation in medium-pressure column |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110392566A (en) * | 2018-02-23 | 2019-10-29 | 株式会社 Lg 生活健康 | Wrinkle-improving composition comprising skatole extract or its fraction as active ingredient |
| CN111012687A (en) * | 2019-12-31 | 2020-04-17 | 中山大学新华学院 | Compound fisetin microemulsion gel and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20170067287A (en) | 2017-06-16 |
| JP2019059761A (en) | 2019-04-18 |
| KR102139659B1 (en) | 2020-07-30 |
| JP2017105777A (en) | 2017-06-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102042967B1 (en) | Cosmetic composition for anti-aging comprising fucosyllactose | |
| US20060233738A1 (en) | Composition for promoting production of type 1 collagen and/or elastin | |
| WO2007037060A1 (en) | Composition for acceleration of type i collagen production | |
| KR20160054668A (en) | Composition for promoting synthesis of hyaluronic acid comprising Taraxacum herbs extracts and the use thereof | |
| US9439849B2 (en) | Composition for preventing or alleviating skin wrinkles containing honeybush extract or fermented honeybush as an active ingredient | |
| CN106852725A (en) | Composition for improving skin | |
| JP2020502172A (en) | Cosmetic composition containing Chinese herbal extract as active ingredient | |
| JP4420358B1 (en) | Hyaluronic acid production promoter | |
| JP6055667B2 (en) | Collagen production promoter | |
| CN109689046A (en) | Comprising phytoestrogen as effective component for preventing hair loss and trichogenous composition | |
| KR20200044307A (en) | Composition for anti-obesity and cellulite reduction comprising mixture of plant extract as effective component | |
| KR20160054673A (en) | Composition for promoting synthesis of hyaluronic acid comprising Portulacae Herba extracts and the use thereof | |
| KR20160054669A (en) | Composition for promoting synthesis of hyaluronic acid comprising Phragmitis Rhizoma extracts and the use thereof | |
| KR102196051B1 (en) | Skin functional composition containing fermented artemisia capillaris | |
| KR101481226B1 (en) | Compositions for improving skin wrinkle or enhancing skin elasticity comprising rebaudioside as an active ingredient | |
| JP2011126814A (en) | Collagen production promoter, hyaluronic acid production promoter, and collagen production and hyaluronic acid production promoter | |
| KR20160054672A (en) | Composition for promoting synthesis of hyaluronic acid comprising Hordeum vulgare extracts and the use thereof | |
| KR20160054681A (en) | Composition for promoting synthesis of hyaluronic acid comprising Polygala tenuifolia Willd extracts and the use thereof | |
| JP2022509002A (en) | Composition and method of applying it to the skin to inhibit cortisone reductase | |
| CN104717957B (en) | Include skin condition improvement composition veratric acid or its salt as active ingredient | |
| JPWO2010137335A1 (en) | Composition for promoting turnover, comprising α-lipoic acid nanoparticles | |
| KR20170136801A (en) | Composition for improving skin conditions | |
| KR101656322B1 (en) | Compositions for improving skin wrinkle or enhancing skin elasticity comprising gardenoside | |
| KR20160054670A (en) | Composition for promoting synthesis of hyaluronic acid comprising jujube extracts and the use thereof | |
| KR20160026443A (en) | Compositions for improving skin wrinkle or enhancing skin elasticity comprising loganic acid |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1236841 Country of ref document: HK |
|
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20170616 |
|
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1236841 Country of ref document: HK |